How Aspirin Lowers Heart Attack and Stroke Risk
Regular low-dose aspirin (typically 75-325 mg daily) reduces the risk of heart attacks and ischemic strokes by inhibiting platelet aggregation, which prevents blood clots. In people with established cardiovascular disease, it cuts the risk of serious vascular events by about 20%.[1][2] The U.S. Preventive Services Task Force recommends it for adults aged 40-59 with a 10% or greater 10-year cardiovascular risk, based on trials like the Physicians' Health Study showing a 44% reduction in myocardial infarction among high-risk men.[3]
Benefits for Colon Cancer Prevention
Long-term aspirin use (at least 5-10 years) lowers colorectal cancer incidence and mortality by 20-40%, particularly for advanced adenomas and proximal colon cancers. Mechanisms involve reduced inflammation and COX-2 enzyme inhibition, as shown in meta-analyses of observational and randomized trials like the Nurses' Health Study.[4][5] Benefits increase with higher doses (300+ mg) but emerge after prolonged use.
Role in Primary Prevention for Healthy Adults
For those without prior heart disease, aspirin's net benefit depends on age and risk. It prevents about 1 heart attack per 1,000 low-risk users over 5 years but raises bleeding risk. Recent guidelines shifted: USPSTF now advises against routine use in adults 60+ due to bleeding outweighing gains in trials like ASPREE and ARRIVE.[6][7]
Potential Benefits for Other Conditions
Aspirin shows promise in reducing ovarian, esophageal, and gastric cancer risks by 10-30% with regular use, linked to anti-inflammatory effects.[8] It may slow cognitive decline in some observational data, though randomized trials like ASPREE found no dementia prevention.[9] Limited evidence suggests benefits for preeclampsia prevention in high-risk pregnancies at 100-150 mg daily.[10]
What Raises Bleeding Risks and Limits Benefits
Daily aspirin doubles the risk of gastrointestinal bleeding (2-4 extra cases per 1,000 users yearly) and increases intracranial hemorrhage by 50%.[11] Risks rise with age over 70, concurrent NSAIDs, steroids, or anticoagulants. H. pylori infection or prior ulcers amplify GI harm; proton pump inhibitors can mitigate this.[12] Net harm often exceeds cardiovascular gains in low-risk groups.
Guidelines: Who Should Start and Who Should Stop
- Start: Secondary prevention (post-heart attack/stroke); primary prevention in select 40-59-year-olds at high CVD risk.[3]
- Avoid: Low-risk adults, those over 60 without CVD, or with bleeding history.[6]
- Dosing: Enteric-coated 81 mg daily minimizes stomach irritation.[2]
Consult a doctor; self-starting ignores individual risks like genetics (e.g., CYP2C9 variants affecting metabolism).
[1]: Antithrombotic Trialists' Collaboration, BMJ (2009). https://www.bmj.com/content/338/bmj.b1204
[2]: American Heart Association Guidelines (2021). https://www.ahajournals.org/doi/10.1161/CIR.0000000000000974
[3]: USPSTF Aspirin Recommendation (2022). https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/aspirin-to-prevent-cardiovascular-disease-preventive-medication
[4]: Rothwell et al., Lancet (2012). https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60342-8/fulltext
[5]: Drew et al., Annals of Internal Medicine (2019). https://www.acpjournals.org/doi/10.7326/M19-0565
[6]: ASPREE Trial, NEJM (2018). https://www.nejm.org/doi/full/10.1056/NEJMoa1805819
[7]: ARRIVE Trial, Lancet (2018). https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31924-X/fulltext
[8]: Huang et al., Journal of Clinical Oncology (2016). https://ascopubs.org/doi/10.1200/JCO.2015.65.4358
[9]: ASPREE Dementia Results, NEJM (2020). https://www.nejm.org/doi/full/10.1056/NEJMoa1913202
[10]: Duley et al., Cochrane Review (2019). https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004659.pub3/full
[11]: McQuaid & Laine, NEJM (2006). https://www.nejm.org/doi/full/10.1056/NEJMra052720
[12]: Bhatt et al., Lancet (2010). https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)60956-3/fulltext